Vimarsana
Biggest News Aggregation in the World

Page 11 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

Pictet Asset Management SA Raises Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Vimarsana News

Pictet Asset Management SA Raises Position in Editas Medicine, Inc. (NASDAQ:EDIT)

Pictet Asset Management SA lifted its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the quarter. Pictet Asset Management […]

Pictet Asset Management SA Has $2.23 Million Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Vimarsana News

Pictet Asset Management SA Has $2.23 Million Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)

Pictet Asset Management SA raised its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 37.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 182,186 shares of the company’s stock after purchasing an additional 49,782 shares during the period. Pictet Asset Management SA […]

Editas Medicine Announces Fourth Quarter and Full Year 2022 - Vimarsana News

Editas Medicine Announces Fourth Quarter and Full Year 2022

Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide...

Editas Medicine (NASDAQ:EDIT) Price Target Cut to $43.00 - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Price Target Cut to $43.00

Editas Medicine (NASDAQ:EDIT – Get Rating) had its price target reduced by investment analysts at Chardan Capital from $60.00 to $43.00 in a report issued on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price objective would suggest a potential upside of 268.47% from the stock’s previous […]

Editas Medicine to Host Conference Call Discussing Second - Vimarsana News

Editas Medicine to Host Conference Call Discussing Second

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will...